FDA Enforcement Class II Ongoing

Tandem pumps are battery-operated infusion pumps capable of both basal and bolus delivery of insulin. The pumps utilize a motor-driven mechanism to deliver insulin from within a disposable cartridge, through an infusion set, into a patient s subcutaneous tissue. As with current insulin infusion pumps on the U.S. market, the desired timing and quantity of the insulin delivery is programmed by the user (i.e., the patient).

Recall: Z-1636-2026 · Reported April 1, 2026

Enforcement

Recall Number
Z-1636-2026
Event ID
98478
Classification
Class II
Status
Ongoing
Product Type
Devices
Firm
Tandem Diabetes Care, Inc.
Voluntary / Mandated
Voluntary: Firm initiated
Initial Notification
Letter
Report Date
April 1, 2026
Initiation Date
January 30, 2026
Classification Date
March 25, 2026
Address
12400 High Bluff Dr, San Diego, CA, 92130-3077, United States

Description

Tandem pumps are battery-operated infusion pumps capable of both basal and bolus delivery of insulin. The pumps utilize a motor-driven mechanism to deliver insulin from within a disposable cartridge, through an infusion set, into a patient s subcutaneous tissue. As with current insulin infusion pumps on the U.S. market, the desired timing and quantity of the insulin delivery is programmed by the user (i.e., the patient).

Reason

The Czech language user guide contained multiple translation errors. The most significant error was that it incorrectly instructs users to verify that the infusion set is connected to the body, when it should instead direct users to confirm that the infusion set is not connected to the body. Following this instruction could result in unintended insulin delivery, potentially leading to a hypoglycemic event.

Code Info

Version 7.8.1/ UDI: (01)008500066132625

Distribution

International distribution in the countries of Czech Republic, Slovakia.

Quantity

1,380 units